Abstract
High-Dose-Rate (HDR) Interstitial brachytherapy has gained increasing acceptance as an alternative to low-dose-rate interstitial brachytherapy for the treatment of select gynecologic cancers. However, there are few reports of efficacy and toxicity data including dose tolerance limits for the proximal versus the distal vagina and adjacent tissue. We report outcomes for patients treated with HDR interstitial brachytherapy at our institution and describe the dosimetric tolerance between the proximal and distal ano-rectum as a surrogate for vaginal tolerance.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Radiation Oncology*Biology*Physics
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
